<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65611">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02112838</url>
  </required_header>
  <id_info>
    <org_study_id>C-935788-050</org_study_id>
    <secondary_id>2014-000331-16</secondary_id>
    <nct_id>NCT02112838</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy</brief_title>
  <official_title>A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigel Pharmaceuticals</source>
  <oversight_info>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hong Kong: Department of Health</authority>
    <authority>Singapore: Health Sciences Authority</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether fostamatinib is safe and effective in the
      treatment of IgA Nephropathy
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean change of proteinuria as measured by spot urine protein/creatinine ratio (sPCR)</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>IGA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Fostamatinib 150 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fostamatinib 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fostamatinib 100 mg tablet twice daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet twice daily by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib 150 mg</intervention_name>
    <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth</description>
    <arm_group_label>Fostamatinib 150 mg</arm_group_label>
    <other_name>R935788</other_name>
    <other_name>R788</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib 100 mg</intervention_name>
    <description>Fostamatinib 100 mg tablet twice daily by mouth</description>
    <arm_group_label>Fostamatinib 100 mg</arm_group_label>
    <other_name>R935788</other_name>
    <other_name>R788</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet twice daily by mouth</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal biopsy findings consistent with IgA nephropathy

          -  Treatment with an Angiotensin Converting Enzyme inhibitor (ACEi) and/or an
             Angiotensin II Receptor Blocker (ARB) for at least 90 days at the maximum approved
             (or tolerated) dose

          -  Proteinuria &gt; 1 gm/day or sPCR &gt; 100 mg/mmol at diagnosis of IgA nephropathy and
             Proteinuria &gt; 0.50 gm/day (sPCR &gt; 50 mg/mmol)  at the second Screening Visit

          -  Blood pressure controlled to â‰¤ 130/80 with angiotensin blockade with or without other
             anti-hypertensive agents

        Exclusion Criteria:

          -  History of or active, clinically significant, respiratory, gastrointestinal
             (including pancreatitis), hepatic, neurological, psychiatric, musculoskeletal,
             genitourinary, dermatological, or other disorder

          -  Have had any major cardiovascular event within the 180 days prior to randomisation,
             including but not limited to: myocardial infarction, unstable angina, cerebrovascular
             accident, pulmonary embolism, or New York Heart Association Class III or IV heart
             failure.

          -  Diagnosis or history suggestive of Henoch-Schonlein purpura

          -  Active bacterial or parasitic infections, including tuberculosis

          -  Positive serologic test for hepatitis B or hepatitis C, or subjects with suspected
             human immunodeficiency virus (HIV)

          -  Prior or current use of corticosteroids (unless for non-renal indications)

          -  Prior or current use of immunosuppressive agents including cyclosporine,
             cyclophosphamide, azathioprine, mycophenolate mofetil, Rituximab (or other anti-B
             cell therapies)

          -  Have a significant infection, an acute infection such as influenza, or who are known
             to have an active inflammatory process at the time of Screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>(Frederick) Wai Keung Tam, MB BChir PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College Renal and Transplant Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Magilavy, MD</last_name>
    <phone>650-624-1372</phone>
  </overall_contact>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>April 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
